via Ocular Surface Center Berlin
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.
“Our work has led to an effective and accessible solution called LiQD Cornea to treat corneal perforations without the need for transplantation,” said Griffith. She is also a full professor in the Department of Ophthalmology at Université de Montréal.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
LiQD Cornea
- Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024
April 27, 2024--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented positive ...
- Risk of infectious illnesses over holiday warns China CDC
China's COVID epidemic has maintained at a low level overall with infection waves occuring from time to time. "But the novel coronavirus is still mutating and the risk of a resurgence remains," it ...
- New structures offer insight into how a bacterial motor powers bacterial chemotaxis, a key infectious process
Bacteria existed for millennia before humans and have been infecting us from the beginning. Although we can treat infections through pharmaceuticals, bacteria continue to become resistant to treatment ...
- Former anti-vaxxer addresses infectious disease conference
Heather Simpson was the keynote speaker Wednesday at the Illinois Department of Public Health’s infectious disease conference at Illinois State University.
- Infectious-materials lab near Fresno was a hidden danger. A bill would tighten laws | Opinion
House Resolution 8065, the Preventing Illegal Laboratories and Protecting Public Health Act, would require labs selling highly infectious agents — viruses, bacteria, parasites — to keep a log of sales ...
Go deeper with Google Headlines on:
LiQD Cornea
[google_news title=”” keyword=”LiQD Cornea” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Corneal perforations
- Eyenovia, Inc.: Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO prese ...
- Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO ...
Go deeper with Google Headlines on:
Corneal perforations
[google_news title=”” keyword=”corneal perforations” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]